Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma.

Estimated overall survival was 76.6% at 4 years in patients who developed endocrinopathy, compared to 66.5% in those without ( Figure 2B ), however this also did not reach statistical significance (p=0.09).

also in 111,027 other papers